Annotation Detail

Information
Associated Genes
FGFR1
Associated Variants
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
Associated Disease
adenosquamous lung carcinoma
Source Database
CIViC Evidence
Description
Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC. Patient was treated with 400 mg pazopanib twice a day. CT taken four and eight weeks after start of pazopanib showed tumor regression and cavitation. Due to side effects, patient stopped taking pazopanib after 6 months. No clinical or radiologic signs of tumor progression were present at that time.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7811
Gene URL
https://civic.genome.wustl.edu/links/genes/1885
Variant URL
https://civic.genome.wustl.edu/links/variants/267
Rating
3
Evidence Type
Predictive
Disease
Adenosquamous Cell Lung Carcinoma
Evidence Direction
Supports
Drug
Pazopanib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
24302556
Drugs
Drug NameSensitivitySupported
PazopanibSensitivitytrue